Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Silence Therapeutics Plc - American Depository Share (NQ:SLN)

3.880 +0.050 (+1.31%)
Streaming Delayed Price Updated: 9:36 AM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Silence Therapeutics Plc - American Depository Share

< Previous 1 2 3 4 5 Next >
Silence Therapeutics Announces Detailed Results From SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at the American College of Cardiology (ACC.22) Annual Meeting
From Silence Therapeutics plc
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022
Upgrades 
Via Benzinga
Silence Therapeutics Posts First Human Data For Cardiovascular Candidate
Silence Therapeutics plc (NASDAQ: SLN) showed that its RNAi technology could  
Via Benzinga
Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Reports Fourth Quarter and Full Year 2021 Results
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Appoints Craig Tooman President and Chief Executive Officer
From Silence Therapeutics plc
Via Business Wire
Earnings Scheduled For March 17, 2022
Companies Reporting Before The Bell • TransGlobe Energy (NASDAQ:TGA) is estimated to report earnings for its fourth quarter. • Ikena Oncology (NASDAQ:IKNA) is... 
Via Benzinga
Silence Therapeutics Announces Positive Topline Data in SLN360 Phase 1 Single-Ascending Dose Study in Healthy Adults with High Lipoprotein(a)
From Silence Therapeutics plc
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 505 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: The company with the largest market cap to... 
Via Benzinga
Silence Therapeutics Announces SLN360 Phase 1 Data Accepted for Late-Breaking Presentation at the American College of Cardiology (ACC) Annual Scientific Session and Expo
From Silence Therapeutics plc
Via Business Wire
51 Biggest Movers From Yesterday
Gainers Sierra Oncology, Inc. (NASDAQ: SRRA) shares climbed 46.2% to close at $22.68 on Tuesday after the company unveiled topline data for momelotinib in myelofibrosis patients... 
Via Benzinga
Silence Therapeutics’ Head of Molecular Design Dr. Marie Wikström Lindholm Appointed to Oligonucleotide Therapeutics Society Board of Directors
From Silence Therapeutics plc
Via Business Wire
The Daily Biotech Pulse: Moderna's Booster Shot Gets FDA Panel Backing, Decision Day For Avadel, Silence Therapeutics Strikes Licensing Deal, MiNK IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Adcom Recommends Approval Of Moderna's COVID-19 Vaccine Booster Shot For... 
Via Benzinga
Exposures COVID-19 Product Safety
Silence Therapeutics plc (SLN) Q2 2021 Earnings Call Transcript
SLN earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Silence Therapeutics' siRNA Candidate Reduces Plasma Iron Levels, Early-Stage Study Shows
Silence Therapeutics plc (NASDAQ: SLN) has announced topline data from GEMINI Phase 1 study evaluating SLN124 for iron-loading anemia conditions, thalassemia, and... 
Via Benzinga
The Daily Biotech Pulse: Iovance To Delay Regulatory Filing For Cancer Therapy, Departures At Passage Bio, Positive Readout For Silence Therapeutics
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18) Alexion Pharmaceuticals, Inc... 
Via Benzinga
Silence Therapeutics Plc (SLN) Q4 2020 Earnings Call Transcript
SLN earnings call for the period ending December 31, 2020. 
Via The Motley Fool
Topics Earnings
Exposures Financial
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Galera Therapeutics (NASDAQ:GRTX) stock rose 21.78% to $8.05 during Thursday's regular session. As of 12:32 EST, Galera Therapeutics's stock is trading at... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.